- CNX-1351
-
- $41.00 / 1mg
-
2024-11-19
- CAS:1276105-89-5
- Min. Order:
- Purity: 99.69%
- Supply Ability: 10g
|
| | CNX-1351 Basic information |
| Product Name: | CNX-1351 | | Synonyms: | 1-[4-[[2-(1H-Indazol-4-yl)-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl]-1-piperazinyl]-6-methyl-5-heptene-1,4-dione CNX1351;CNX-1351, >=98%;CNX-1351;1-[4-[[2-(1H-Indazol-4-yl)-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl]-1-piperazinyl]-6-methyl-5-heptene-1,4-dione;1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-6-methylhept-5-ene-1,4-dione;CS-1069;CNX-1351; CNX 1351; CNX1351;CNX1351cas | | CAS: | 1276105-89-5 | | MF: | C30H35N7O3S | | MW: | 573.71 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1276105-89-5.mol |  |
| | CNX-1351 Chemical Properties |
| density | 1.328±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 33.33 mg/mL (58.10 mM; Need ultrasonic) | | form | Powder | | pka | 12.22±0.40(Predicted) | | color | White to yellow |
| | CNX-1351 Usage And Synthesis |
| Biological Activity | CNX-1351 is a potent and selective PI3Kα inhibitor with IC50 of 6.8 nM. | | in vivo | CNX-1351 inhibits p-Akt Ser473 in mouse spleens and bonds to PI3Kα in vivo. It is delivered into the intraperitoneal cavity of nude mice at 100 mg/kg once a day for 5 consecutive days (n=3 mice per group). | | target | | PI3Kα 6.8 nM (IC 50 ) | PI3Kβ 166 nM (IC 50 ) | PI3Kδ 240.3 nM (IC 50 ) | PI3Kγ 3020 nM ( IC 50 ) | |
| | CNX-1351 Preparation Products And Raw materials |
|